“Semaglutide May Reduce Cardiovascular Risks in Heart Failure Patients with Preserved Ejection Fraction and Obesity”

https://pubmed.ncbi.nlm.nih.gov/38118034

The abstract suggests that semaglutide, a glucagon-like peptide-1 receptor agonist, may reduce the risk of cardiovascular events in patients with heart failure with preserved ejection fraction and obesity.